| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fece74aa8c0cb73d997c194165159cc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate |
2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e382238cfc77c6ab46f712375b03654
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29e64fd45417ed08eb15f8dea9b44a8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca0f6e7600bc81842241d2d109ffe00d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f540b3882adadee51d40329f25431fc |
| publicationDate |
2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021176083-A1 |
| titleOfInvention |
Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |
| abstract |
Pharmaceutical compositions comprising dasatinib anhydrous provide an improved, pH-independent dissolution profile compared with pharmaceutical compositions comprising dasatinib monohydrate. Thus, pharmaceutical compositions comprising dasatinib anhydrous can be used in the treatment of chronic myelogenous leukaemia (CML) and/or Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL), especially in subjects having an increased gastric pH and/or in subjects being co-administered with a gastric acid reducing agent. |
| priorityDate |
2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |